Weigao’s Profit Drops Despite Modest Revenue Growth and Dividend Cut

Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) just unveiled an update.

Shandong Weigao Group Medical Polymer Company Limited, a major Chinese medical device producer specializing in polymer-based products and hospital consumables, operates in the broader healthcare and medtech sector with a focus on serving clinical institutions at home and abroad. Its diversified portfolio and scale give it a meaningful position in China’s fast-evolving medical devices market.

For 2025, the group reported a 2.3% rise in revenue to RMB13.39 billion but a 22% drop in net profit attributable to shareholders to RMB1.61 billion, reflecting higher costs, increased expenses and exchange losses. Adjusted net profit excluding extraordinary items and currency effects also declined nearly 20%, while the board proposed cutting the final dividend to RMB0.06 per share, signalling margin pressure and a more cautious capital return stance for investors despite modest top-line growth.

The most recent analyst rating on (HK:1066) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

More about Shandong Weigao Group Medical Polymer Co

Shandong Weigao Group Medical Polymer Company Limited is a PRC-based medical device manufacturer focused on medical polymer products and related consumables. Listed in Hong Kong, the group supplies a broad range of hospital-use products, positioning itself within China’s healthcare and medical technology sector and serving both domestic and overseas markets.

Average Trading Volume: 15,774,087

Technical Sentiment Signal: Sell

Current Market Cap: HK$20.08B

Find detailed analytics on 1066 stock on TipRanks’ Stock Analysis page.